WO2000033788A3 - Substituted nitrogen heterocyclic compounds and therapeutic uses thereof - Google Patents

Substituted nitrogen heterocyclic compounds and therapeutic uses thereof Download PDF

Info

Publication number
WO2000033788A3
WO2000033788A3 PCT/US1999/028374 US9928374W WO0033788A3 WO 2000033788 A3 WO2000033788 A3 WO 2000033788A3 US 9928374 W US9928374 W US 9928374W WO 0033788 A3 WO0033788 A3 WO 0033788A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic uses
heterocyclic compounds
substituted nitrogen
nitrogen heterocyclic
compounds
Prior art date
Application number
PCT/US1999/028374
Other languages
French (fr)
Other versions
WO2000033788A2 (en
Inventor
Jacob Szmuszkovicz
Ciaran M Regan
Original Assignee
American Biogenetic Sciences
Univ Dublin
Jacob Szmuszkovicz
Ciaran M Regan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Biogenetic Sciences, Univ Dublin, Jacob Szmuszkovicz, Ciaran M Regan filed Critical American Biogenetic Sciences
Priority to EP99965946A priority Critical patent/EP1137412A4/en
Priority to CA002355296A priority patent/CA2355296A1/en
Priority to AU21609/00A priority patent/AU2160900A/en
Publication of WO2000033788A2 publication Critical patent/WO2000033788A2/en
Publication of WO2000033788A3 publication Critical patent/WO2000033788A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to substituted nitrogen heterocyclic compounds having general formulas (1) and (2). This invention further relates to pharmaceutical compositions comprising these compounds, and therapeutic uses of such compositions for treating or controlling the symptoms of memory loss, Alzheimer's disease, senile dementia or similar conditions.
PCT/US1999/028374 1998-12-11 1999-12-01 Substituted nitrogen heterocyclic compounds and therapeutic uses thereof WO2000033788A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99965946A EP1137412A4 (en) 1998-12-11 1999-12-01 Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
CA002355296A CA2355296A1 (en) 1998-12-11 1999-12-01 Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
AU21609/00A AU2160900A (en) 1998-12-11 1999-12-01 Substituted nitrogen heterocyclic compounds and therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11183998P 1998-12-11 1998-12-11
US60/111,839 1998-12-11

Publications (2)

Publication Number Publication Date
WO2000033788A2 WO2000033788A2 (en) 2000-06-15
WO2000033788A3 true WO2000033788A3 (en) 2000-10-19

Family

ID=22340712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/028374 WO2000033788A2 (en) 1998-12-11 1999-12-01 Substituted nitrogen heterocyclic compounds and therapeutic uses thereof

Country Status (4)

Country Link
EP (1) EP1137412A4 (en)
AU (1) AU2160900A (en)
CA (1) CA2355296A1 (en)
WO (1) WO2000033788A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2819511A1 (en) * 2001-01-18 2002-07-19 Servier Lab New N-substituted azepane or azepanone derivatives, are selective farnesyl transferase inhibitors useful for treating cancer diseases, restenosis or type I neurofibromatosis
WO2004002483A1 (en) * 2002-06-27 2004-01-08 Actelion Pharmaceuticals Ltd Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer’s disease
MXPA06012831A (en) * 2004-05-06 2007-01-26 Pfizer Novel compounds of proline and morpholine derivatives.
JP2006143667A (en) * 2004-11-22 2006-06-08 Ube Ind Ltd Pipecolic acid amide derivative and antibacterial agent
UA100227C2 (en) 2006-07-06 2012-12-10 Глаксо Груп Лімітед Substituted n-phenylmethyl-5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
WO2009074518A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
JP5583694B2 (en) * 2009-01-05 2014-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrrolidine compounds that modulate the CB2 receptor
CN110240557B (en) 2018-03-08 2023-05-09 广东东阳光药业有限公司 Pyrrolidine amide derivatives and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608056A (en) * 1992-04-13 1997-03-04 Fujisawa Pharmaceutical Co., Ltd. Substituted 3-pyrrolidinylthio-carbapenems as antimicrobial agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1039731A (en) * 1974-12-18 1978-10-03 Synthelabo Process for preparing new 2-methoxy-benzamide derivatives
FI95572C (en) * 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
JPH02104568A (en) * 1988-06-22 1990-04-17 Yoshitomi Pharmaceut Ind Ltd Acting agent of production promotion of nerve growth factor
CN1029227C (en) * 1989-02-08 1995-07-05 大制药株式会社 Composition for denatured denaturation or protection agent for nerve cell and process for preparing benzene derivatives used for composition
US5446147A (en) * 1992-04-03 1995-08-29 Trustees Of The University Of Pennsylvania Fluorinated and iodinated dopamine agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608056A (en) * 1992-04-13 1997-03-04 Fujisawa Pharmaceutical Co., Ltd. Substituted 3-pyrrolidinylthio-carbapenems as antimicrobial agents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CAN. J. CHEM.,, vol. 51, no. 2, 1973, pages 208 - 214 *
DATABASE CAS ONLINE, 1973, MARINIER ET AL.: "2,2,2-Trichloroethyl group for carboxyl protection during peptide synthesis", XP002949874 *
DATABASE CAS ONLINE, BAXTER ET AL.: "Expeditious Synthesis of Aza sugars by the Double Reductive Amination of Dicarbonyl Sugars", XP002949873 *
DATABASE CAS ONLINE, CALVEZ ET AL.: "Enantioselective synthesis of 2,3-disubstituted piperidines from (S)-methyl pyroglutamate", XP002949872 *
J. ORG. CHEM.,, vol. 59, no. 11, 1994, pages 3175 - 3185 *
See also references of EP1137412A4 *
TETRAHEDRON LETT.,, vol. 39, no. 51, 1998, pages 9447 - 9450 *

Also Published As

Publication number Publication date
WO2000033788A2 (en) 2000-06-15
CA2355296A1 (en) 2000-06-15
EP1137412A2 (en) 2001-10-04
EP1137412A4 (en) 2002-04-03
AU2160900A (en) 2000-06-26

Similar Documents

Publication Publication Date Title
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
WO2000038618A3 (en) SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
WO2001066564A3 (en) Gamma-secretase inhibitors
CA2343236A1 (en) 4,4-biarylpiperidine derivatives
CA2361998A1 (en) Aromatic heterocyclic compounds as anti-inflammatory agents
WO2003047577A3 (en) Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses
MY132671A (en) Substituted 6,6-hetero-bicyclic derivatives
CA2274464A1 (en) Ketobenzamides as calpain inhibitors
CA2362003A1 (en) Heterocyclic urea and related compounds useful as anti-inflammatory agents
WO2002016357A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO1999063999A8 (en) H1-histamine receptor antagonists
WO2002016358A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
CA2080705A1 (en) Substituted pyrimidines
CA2338220A1 (en) Substituted imidazoles having cytokine inhibitory activity
ZA979961B (en) 5-HT1F agonists
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
WO2002016369A3 (en) Novel macrocycles and uses thereof
CA2237189A1 (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
BG105731A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
WO2001019797A3 (en) HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
WO1999012933A3 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
WO2000033788A3 (en) Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
IL135634A0 (en) 5-htif agonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2355296

Country of ref document: CA

Ref country code: CA

Ref document number: 2355296

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999965946

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999965946

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09857991

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999965946

Country of ref document: EP